Lindsey Shapiro, PhD, science writer —

Lindsey earned her PhD in neuroscience from Emory University in Atlanta, where she studied novel therapeutic strategies for treatment-resistant forms of epilepsy. She was awarded a fellowship from the American Epilepsy Society in 2019 for this research. Lindsey also previously worked as a postdoctoral researcher, studying the role of inflammation in epilepsy and Alzheimer’s disease.

Articles by Lindsey Shapiro

FDA OKs less frequent Tecvayli dosing for treatment responders

The U.S. Food and Drug Administration (FDA) has cleared an every-other-week dosing regimen of Tecvayli (teclistamab) for relapsed or refractory (hard-to-treat) multiple myeloma (RRMM) patients who have responded well to the therapy’s standard weekly dosing. Tecvayli was initially approved in 2022 for adults with RRMM who had…

Regeneron seeking approval of linvoseltamab for RRMM in US, EU

The European Medicines Agency has agreed to review Regeneron Pharmaceuticals’ application seeking approval of its investigational therapy linvoseltamab for adults in Europe with relapsed or refractory multiple myeloma (RRMM), according to a company press release. A similar application was submitted to the U.S. Food and Drug Administration…

Xpovio combo plus mezigdomide to be tested in relapsed-refractory MM

A Phase 1/2 clinical trial will evaluate the safety and efficacy oral mezigdomide, Bristol-Myers Squibb’s investigational treatment, when added to the approved oral combination of Xpovio (selinexor) plus dexamethasone in people with difficult-to-treat multiple myeloma. Under the terms of a trial collaboration and supply agreement,…

Elranatamab, now Elrexfio, approved for hard-to-treat myeloma

The U.S. Food and Drug Administration (FDA) has granted conditional approval to Pfizer‘s elranatamab — an antibody therapy to be marketed under the brand name Elrexfio — for adults with difficult-to-treat multiple myeloma. Eligible patients will have received at least four prior lines of therapy, including a…

ISB 1442 antibody therapy wins US orphan drug status

ISB 1442, Ichnos Sciences’ investigational bi-specific antibody-based treatment, has earned orphan drug designation from the U.S. Food and Drug Administration (FDA) for treating relapsed or refractory multiple myeloma. The designation is awarded to therapies that show promise for rare diseases, those affecting fewer than 200,000 people in the U.S.